董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark A. Beck | 男 | Chair of the Board and Independent Director | 60 | 46.00万美元 | 未持股 | 2026-05-14 |
| Gwendolyn M. Bingham | 女 | Independent Director | 66 | 35.50万美元 | 未持股 | 2026-05-14 |
| Stephen W. Klemash | 男 | Independent Director | 65 | 36.00万美元 | 未持股 | 2026-05-14 |
| Kenneth Gardner Smith | 男 | Independent Director | 45 | 34.88万美元 | 未持股 | 2026-05-14 |
| Teresa L. Kline | 女 | Independent Director | 67 | 33.00万美元 | 未持股 | 2026-05-14 |
| Edward A. Pesicka | 男 | Chief Executive Officer and Director and President | 58 | 1115.78万美元 | 未持股 | 2026-05-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew G. Long | 男 | Executive Vice President, Chief Executive Officer, Products & Healthcare Services | 60 | 358.72万美元 | 未持股 | 2026-05-14 |
| Jonathan A. Leon | 男 | Chief Financial Officer and Executive Vice President | 59 | 296.27万美元 | 未持股 | 2026-05-14 |
| Perry A. Bernocchi | 男 | Chief Operating Officer and Executive Vice President | 67 | 342.36万美元 | 未持股 | 2026-05-14 |
| Heath H. Galloway | 男 | Corporate Secretary and Executive Vice President and General Counsel | 49 | 229.46万美元 | 未持股 | 2026-05-14 |
| Edward A. Pesicka | 男 | Chief Executive Officer and Director and President | 58 | 1115.78万美元 | 未持股 | 2026-05-14 |
董事简历
中英对照 | 中文 | 英文- Mark A. Beck
-
Mark A. Beck，自2020年9月起担任董事会主席，是B-Square Precision， LLC的联合创始人和所有者，B-Square Precision， LLC是一家私营公司，从事收购和管理制造高精度工具、模具、模具和组件的公司。此前，Beck先生于2015年11月至2018年2月担任世界上最大的门窗制造商之一JELD-WEN Holding， Inc. （JELD-WEN）的总裁兼首席执行官，并于2016年5月至2018年2月担任JELD-WEN的董事。在加入JELD-WEN之前，Beck先生从2014年4月开始担任Danaher Corporation的执行副总裁，领导Danaher的水质和牙科平台。此前，他在Corning Incorporated工作了18年，担任一系列管理职位，责任越来越大，最终于2012年7月被任命为执行副总裁，负责监督康宁的环境技术和生命科学部门。Beck先生目前任职于IDEX Corporation的董事会，在那里他担任提名和公司治理委员会主席，也是薪酬委员会的成员。他还担任kdc/one （KKR和Cornell Capital赞助的私人控股公司）的董事会成员。2010年至2014年，他曾担任dowcorning Corporation的董事会成员。
Mark A. Beck serves as the Board's Chair, a position he has held since September 2020, and is the co founder and owner of B Square Precision, LLC, a private company engaged in the acquisition and management of companies that manufacture high precision tools, dies, molds and components. Previously, Mr. Beck served as President and Chief Executive Officer of JELD WEN Holding, Inc. (JELD WEN), one of the world's largest door and window manufacturers, from November 2015 to February 2018, and was a director of JELD WEN from May 2016 to February 2018. Prior to JELD WEN, Mr. Beck served as an Executive Vice President at Danaher Corporation, leading Danaher's water quality and dental platforms, beginning in April 2014. Previously, he spent 18 years with Corning Incorporated in a series of management positions with increasing responsibility, culminating in his appointment as Executive Vice President overseeing Corning's environmental technologies and life science units in July 2012. In 2025, Mr. Beck was appointed visiting Professor of Practice at Cornell University, teaching courses on leadership, strategy, and innovation at the MBA, master of engineering and undergraduate levels. Mr. Beck currently serves on the board of directors of IDEX Corporation where he chairs the Nominating and Corporate Governance Committee and is a member of the Compensation Committee. Mr. Beck also serves on the board of kdc/one, a privately held company sponsored by KKR and Cornell Capital. He formerly served on the board of directors of Dow Corning Corporation from 2010 to 2014. - Mark A. Beck，自2020年9月起担任董事会主席，是B-Square Precision， LLC的联合创始人和所有者，B-Square Precision， LLC是一家私营公司，从事收购和管理制造高精度工具、模具、模具和组件的公司。此前，Beck先生于2015年11月至2018年2月担任世界上最大的门窗制造商之一JELD-WEN Holding， Inc. （JELD-WEN）的总裁兼首席执行官，并于2016年5月至2018年2月担任JELD-WEN的董事。在加入JELD-WEN之前，Beck先生从2014年4月开始担任Danaher Corporation的执行副总裁，领导Danaher的水质和牙科平台。此前，他在Corning Incorporated工作了18年，担任一系列管理职位，责任越来越大，最终于2012年7月被任命为执行副总裁，负责监督康宁的环境技术和生命科学部门。Beck先生目前任职于IDEX Corporation的董事会，在那里他担任提名和公司治理委员会主席，也是薪酬委员会的成员。他还担任kdc/one （KKR和Cornell Capital赞助的私人控股公司）的董事会成员。2010年至2014年，他曾担任dowcorning Corporation的董事会成员。
- Mark A. Beck serves as the Board's Chair, a position he has held since September 2020, and is the co founder and owner of B Square Precision, LLC, a private company engaged in the acquisition and management of companies that manufacture high precision tools, dies, molds and components. Previously, Mr. Beck served as President and Chief Executive Officer of JELD WEN Holding, Inc. (JELD WEN), one of the world's largest door and window manufacturers, from November 2015 to February 2018, and was a director of JELD WEN from May 2016 to February 2018. Prior to JELD WEN, Mr. Beck served as an Executive Vice President at Danaher Corporation, leading Danaher's water quality and dental platforms, beginning in April 2014. Previously, he spent 18 years with Corning Incorporated in a series of management positions with increasing responsibility, culminating in his appointment as Executive Vice President overseeing Corning's environmental technologies and life science units in July 2012. In 2025, Mr. Beck was appointed visiting Professor of Practice at Cornell University, teaching courses on leadership, strategy, and innovation at the MBA, master of engineering and undergraduate levels. Mr. Beck currently serves on the board of directors of IDEX Corporation where he chairs the Nominating and Corporate Governance Committee and is a member of the Compensation Committee. Mr. Beck also serves on the board of kdc/one, a privately held company sponsored by KKR and Cornell Capital. He formerly served on the board of directors of Dow Corning Corporation from 2010 to 2014.
- Gwendolyn M. Bingham
-
Gwendolyn M.Bingham在军队工作了38年后，于2019年9月从美国陆军退休。在她的军事生涯中，LTG从2016年到2019年退休，宾厄姆曾担任陆军安装管理助理参谋长。此前，她曾担任美国陆军坦克-汽车和武器生命周期管理司令部司令（2014年至2016年）、白沙导弹靶场司令（2012年至2014年）、美国陆军军需学校司令（2010年至2012年），以及参谋长，联合武器支助指挥和维持英才中心，2008年至2010年。LTG（已退休）宾厄姆拥有众多公民和军事荣誉，是第一位担任过多个美国陆军将军职位的女性，其中包括:陆军第51军需官兼弗吉尼亚州李堡美国陆军军需官学校司令；白沙导弹靶场司令，新墨西哥州，担任密歇根州沃伦的坦克-汽车和武器生命周期管理司令部的总指挥。
Gwendolyn M. Bingham retired in September 2019 from the U.S. Army following a 38 year career in the military. During her military career, LTG (retired) Bingham served as Department of the Army Assistant Chief of Staff for Installation Management from 2016 through her retirement in 2019. Previously, she was Commanding General, U.S. Army Tank Automotive and Armaments Lifecycle Management Command from 2014 to 2016; Commanding General, White Sands Missile Range from 2012 to 2014; Commandant, U.S. Army Quartermaster School from 2010 to 2012; and Chief of Staff, Combined Arms Support Command and Sustainment Center of Excellence from 2008 to 2010. LTG (retired) Bingham holds numerous civic and military honors commensurate with her rank and lauded achievements. LTG (retired) Bingham serves on the board of SitelogIQ, a privately held company, since January 2021. She previously served on the board of Exactech, Inc, a privately held company from 2021 to October 2025. - Gwendolyn M.Bingham在军队工作了38年后，于2019年9月从美国陆军退休。在她的军事生涯中，LTG从2016年到2019年退休，宾厄姆曾担任陆军安装管理助理参谋长。此前，她曾担任美国陆军坦克-汽车和武器生命周期管理司令部司令（2014年至2016年）、白沙导弹靶场司令（2012年至2014年）、美国陆军军需学校司令（2010年至2012年），以及参谋长，联合武器支助指挥和维持英才中心，2008年至2010年。LTG（已退休）宾厄姆拥有众多公民和军事荣誉，是第一位担任过多个美国陆军将军职位的女性，其中包括:陆军第51军需官兼弗吉尼亚州李堡美国陆军军需官学校司令；白沙导弹靶场司令，新墨西哥州，担任密歇根州沃伦的坦克-汽车和武器生命周期管理司令部的总指挥。
- Gwendolyn M. Bingham retired in September 2019 from the U.S. Army following a 38 year career in the military. During her military career, LTG (retired) Bingham served as Department of the Army Assistant Chief of Staff for Installation Management from 2016 through her retirement in 2019. Previously, she was Commanding General, U.S. Army Tank Automotive and Armaments Lifecycle Management Command from 2014 to 2016; Commanding General, White Sands Missile Range from 2012 to 2014; Commandant, U.S. Army Quartermaster School from 2010 to 2012; and Chief of Staff, Combined Arms Support Command and Sustainment Center of Excellence from 2008 to 2010. LTG (retired) Bingham holds numerous civic and military honors commensurate with her rank and lauded achievements. LTG (retired) Bingham serves on the board of SitelogIQ, a privately held company, since January 2021. She previously served on the board of Exactech, Inc, a privately held company from 2021 to October 2025.
- Stephen W. Klemash
-
Stephen W.Klemash自1997年以来一直担任Ernst&Young LLP EY的合伙人，目前是EY Americas Center for Board Matters（CBM）的首席合伙人，他自2016年以来一直担任该职位。在此之前，Klemash先生曾担任EY的多个管理合伙人职位，包括2011年至2016年担任East Central和Central Accounts的管理合伙人，2009年至2011年担任East Central Region Advisory的管理合伙人，从2007年到2009年担任保证和咨询业务服务的中北部地区管理合伙人，从2002年到2007年担任匹兹堡办事处管理合伙人。在2002年之前，Klemash先生是一名保险从业人员，从1984年被EY聘用之日起，为各种行业的客户服务。Klemash先生是一名注册会计师和美国注册会计师协会（American Institute of Certified Public Accountants）的成员。
Stephen W. Klemash retired in June 2021 as a Partner with Ernst & Young LLP (EY), a position he held since 1997. Mr. Klemash served in a limited consulting capacity with EY through June 2022. In addition, Mr. Klemash also previously served as the Lead Partner with the EY Americas Center for Board Matters (CBM), from 2016 to December 2021. Prior to that Mr. Klemash held multiple Managing Partner positions for EY including from 2011 to 2016 East Central and Central Managing Partner of Accounts, from 2009 to 2011 East Central Region Managing Partner of Advisory, from 2007 to 2009 North Central Region Managing Partner of Assurance and Advisory Business Services and from 2002 to 2007 Pittsburgh Office Managing Partner. Prior to 2002, Mr. Klemash was an assurance practitioner, from the date of his hire by EY in 1984, serving clients in a variety of industries. Mr. Klemash is a certified public accountant and member of the American Institute of Certified Public Accountants. - Stephen W.Klemash自1997年以来一直担任Ernst&Young LLP EY的合伙人，目前是EY Americas Center for Board Matters（CBM）的首席合伙人，他自2016年以来一直担任该职位。在此之前，Klemash先生曾担任EY的多个管理合伙人职位，包括2011年至2016年担任East Central和Central Accounts的管理合伙人，2009年至2011年担任East Central Region Advisory的管理合伙人，从2007年到2009年担任保证和咨询业务服务的中北部地区管理合伙人，从2002年到2007年担任匹兹堡办事处管理合伙人。在2002年之前，Klemash先生是一名保险从业人员，从1984年被EY聘用之日起，为各种行业的客户服务。Klemash先生是一名注册会计师和美国注册会计师协会（American Institute of Certified Public Accountants）的成员。
- Stephen W. Klemash retired in June 2021 as a Partner with Ernst & Young LLP (EY), a position he held since 1997. Mr. Klemash served in a limited consulting capacity with EY through June 2022. In addition, Mr. Klemash also previously served as the Lead Partner with the EY Americas Center for Board Matters (CBM), from 2016 to December 2021. Prior to that Mr. Klemash held multiple Managing Partner positions for EY including from 2011 to 2016 East Central and Central Managing Partner of Accounts, from 2009 to 2011 East Central Region Managing Partner of Advisory, from 2007 to 2009 North Central Region Managing Partner of Assurance and Advisory Business Services and from 2002 to 2007 Pittsburgh Office Managing Partner. Prior to 2002, Mr. Klemash was an assurance practitioner, from the date of his hire by EY in 1984, serving clients in a variety of industries. Mr. Klemash is a certified public accountant and member of the American Institute of Certified Public Accountants.
- Kenneth Gardner Smith
-
Kenneth Gardner Smith，自2024年12月起担任Veritas Veterinary Partners首席执行官。Gardner-Smith先生于2020年至2024年4月期间担任世界500强肾透析服务提供商达维塔保健公司的首席人事官。在此之前，Gardner-Smith先生曾在达维塔保健担任以下职位，包括2015年至2019年的区域集团副总裁、现场运营–东南，2014年至2015年的部门副总裁，2013年至2014年的集团董事，以及2011年至2013年的区域运营总监。在2008年至2011年受雇于达维塔保健之前，Gardner-Smith先生曾在摩根士丹利担任投资银行家，专注于并购业务。从2003年到2006年，Gardner-Smith先生担任富国银行的客户关系经理。
Kenneth Gardner Smith has served as the Chief Executive Officer of Veritas Veterinary Partners since December 2024. Mr. Gardner Smith served from 2020 to April 2024 as the Chief People Officer for DaVita, Inc., a Fortune 500 kidney dialysis service provider. Prior to that Mr. Gardner Smith held the following positions with DaVita, including Regional Group VP, Field Operations – Southeast from 2015 to 2019, Division VP from 2014 to 2015, Group Director from 2013 to 2014, and Regional Director, Operations from 2011 to 2013. Prior to his employment with DaVita from 2008 to 2011, Mr. Gardner Smith worked as an investment banker at Morgan Stanley focused on mergers and acquisitions. From 2003 to 2006, Mr. Gardner Smith was a Relationship Manager for Wells Fargo. - Kenneth Gardner Smith，自2024年12月起担任Veritas Veterinary Partners首席执行官。Gardner-Smith先生于2020年至2024年4月期间担任世界500强肾透析服务提供商达维塔保健公司的首席人事官。在此之前，Gardner-Smith先生曾在达维塔保健担任以下职位，包括2015年至2019年的区域集团副总裁、现场运营–东南，2014年至2015年的部门副总裁，2013年至2014年的集团董事，以及2011年至2013年的区域运营总监。在2008年至2011年受雇于达维塔保健之前，Gardner-Smith先生曾在摩根士丹利担任投资银行家，专注于并购业务。从2003年到2006年，Gardner-Smith先生担任富国银行的客户关系经理。
- Kenneth Gardner Smith has served as the Chief Executive Officer of Veritas Veterinary Partners since December 2024. Mr. Gardner Smith served from 2020 to April 2024 as the Chief People Officer for DaVita, Inc., a Fortune 500 kidney dialysis service provider. Prior to that Mr. Gardner Smith held the following positions with DaVita, including Regional Group VP, Field Operations – Southeast from 2015 to 2019, Division VP from 2014 to 2015, Group Director from 2013 to 2014, and Regional Director, Operations from 2011 to 2013. Prior to his employment with DaVita from 2008 to 2011, Mr. Gardner Smith worked as an investment banker at Morgan Stanley focused on mergers and acquisitions. From 2003 to 2006, Mr. Gardner Smith was a Relationship Manager for Wells Fargo.
- Teresa L. Kline
-
Teresa L. Kline于2019年退休，担任密歇根州健康联盟计划总裁兼首席执行官和亨利福特健康系统执行副总裁，自2016年起担任该职位。在此之前，她在医疗保健领域40 +年的经验包括在Health Care Service Corporation（高级副总裁兼首席健康护理管理官）、HealthSouth（高级副总裁）、CHA Health（首席执行官）、United Health Group（UHC-GA首席执行官）、OnCare（高级副总裁）和Aetna Health Plans（区域副总裁）担任执行职务。Kline女士目前在家庭健康和临终关怀公司Amedisys, Inc.的上市公司董事会任职；在移动解决方案公司National Mobility & Seating的私营公司董事会任职；在门诊阿片类药物欧麦斯-麦能医疗e紊乱治疗提供商SAVida Health以及Presbyterian Healthcare Services的健康系统任职。克莱恩女士还担任卡拉马祖学院的董事会成员。此前，克莱恩女士曾担任两家私营医疗保健技术公司Medecision和Availity的董事长。Kline女士曾任职于Apria, Inc.的董事会，直到2022年3月被Owens & Minor, Inc.和Intersect ENT收购，直到2022年5月被美敦力，Inc.收购。
Teresa L. Kline retired in 2019 as President and Chief Executive Officer of Health Alliance Plan of Michigan and Executive Vice President of Henry Ford Health System, positions she held since 2016. Prior to that, her 40+ years of experience in healthcare include executive roles at Health Care Service Corporation (Senior Vice President and Chief Health Care Management Officer), HealthSouth (Senior Vice President), CHA Health (Chief Executive Officer), United Health Group (Chief Executive Officer of UHC GA), OnCare (Senior Vice President) and Aetna Health Plans (Regional Vice President). Ms. Kline currently serves on the private company board of directors of National Mobility & Seating, a mobility solutions company, SaVida Health, an outpatient opioid use disorder treatment provider, and Presbyterian Healthcare Services, a health system. Previously, Ms. Kline served on the public company board of directors of Amedisys, Inc., a home health and hospice company, until it was acquired in August 2025 by United Health Group's Optum (committee service: Audit, Compensation, Governance). Ms. Kline also serves on the board of Kalamazoo College. Previously, Ms. Kline served as the Chairman of two private health care technology companies, Medecision and Availity. Ms. Kline formerly served on the board of directors of Apria, Inc., until it was acquired in March 2022 by Accendra Health, Inc., and Intersect ENT, until it was acquired in May 2022 by Medtronic, Inc. (committee service: Audit, Compensation, Governance). - Teresa L. Kline于2019年退休，担任密歇根州健康联盟计划总裁兼首席执行官和亨利福特健康系统执行副总裁，自2016年起担任该职位。在此之前，她在医疗保健领域40 +年的经验包括在Health Care Service Corporation（高级副总裁兼首席健康护理管理官）、HealthSouth（高级副总裁）、CHA Health（首席执行官）、United Health Group（UHC-GA首席执行官）、OnCare（高级副总裁）和Aetna Health Plans（区域副总裁）担任执行职务。Kline女士目前在家庭健康和临终关怀公司Amedisys, Inc.的上市公司董事会任职；在移动解决方案公司National Mobility & Seating的私营公司董事会任职；在门诊阿片类药物欧麦斯-麦能医疗e紊乱治疗提供商SAVida Health以及Presbyterian Healthcare Services的健康系统任职。克莱恩女士还担任卡拉马祖学院的董事会成员。此前，克莱恩女士曾担任两家私营医疗保健技术公司Medecision和Availity的董事长。Kline女士曾任职于Apria, Inc.的董事会，直到2022年3月被Owens & Minor, Inc.和Intersect ENT收购，直到2022年5月被美敦力，Inc.收购。
- Teresa L. Kline retired in 2019 as President and Chief Executive Officer of Health Alliance Plan of Michigan and Executive Vice President of Henry Ford Health System, positions she held since 2016. Prior to that, her 40+ years of experience in healthcare include executive roles at Health Care Service Corporation (Senior Vice President and Chief Health Care Management Officer), HealthSouth (Senior Vice President), CHA Health (Chief Executive Officer), United Health Group (Chief Executive Officer of UHC GA), OnCare (Senior Vice President) and Aetna Health Plans (Regional Vice President). Ms. Kline currently serves on the private company board of directors of National Mobility & Seating, a mobility solutions company, SaVida Health, an outpatient opioid use disorder treatment provider, and Presbyterian Healthcare Services, a health system. Previously, Ms. Kline served on the public company board of directors of Amedisys, Inc., a home health and hospice company, until it was acquired in August 2025 by United Health Group's Optum (committee service: Audit, Compensation, Governance). Ms. Kline also serves on the board of Kalamazoo College. Previously, Ms. Kline served as the Chairman of two private health care technology companies, Medecision and Availity. Ms. Kline formerly served on the board of directors of Apria, Inc., until it was acquired in March 2022 by Accendra Health, Inc., and Intersect ENT, until it was acquired in May 2022 by Medtronic, Inc. (committee service: Audit, Compensation, Governance).
- Edward A. Pesicka
-
Edward A. Pesicka，他是Owens & Minor， Inc.的总裁兼首席执行官，自2019年3月以来一直担任该职位。此前，Pesicka先生自2016年1月1日起担任医疗保健、生命科学和分销行业的独立顾问和顾问。从2000年1月到2015年4月，他担任Thermo Fisher Scientific Inc.的各种职务，包括首席商务官和高级副总裁（从2014年1月到2015年4月）。在此之前，他从2008年7月到2014年1月担任Thermo Fisher的客户渠道总裁，从2006年11月到2008年7月担任研究市场总裁。在他的职业生涯早期，他在Thermo Fischer Scientific的财务部门担任过各种副总裁级别的职位，担任多个部门的首席财务官。在加入Thermo Fisher Scientific之前，他在TRW， Inc.的财务部门工作了8年，在PricewaterhouseCoopers担任审计员3年。Pesicka先生担任Fortrea的上市公司董事会成员，在那里他是审计委员会和管理发展与薪酬委员会的成员。
Edward A. Pesicka is the President and Chief Executive Officer of Accendra Health, Inc. a position he has held since March 2019. Previously Mr. Pesicka served as an independent consultant and advisor in the healthcare, life sciences and distribution industries since January 1, 2016. From January 2000 through April 2015, Mr. Pesicka served in various roles of increasing responsibility at Thermo Fisher Scientific Inc., including, Chief Commercial Officer and Senior Vice President from January 2014 to April 2015. Prior to that, he was President, Customer Channels at Thermo Fisher from July 2008 to January 2014 and President, Research Market from November 2006 to July 2008. Earlier in his career, Mr. Pesicka held various Vice President level roles in Thermo Fischer Scientific's finance department, serving as Chief Financial Officer of numerous divisions. Prior to Thermo Fisher Scientific, Mr. Pesicka spent eight years with TRW, Inc. in its finance department and three years with PricewaterhouseCoopers as an auditor. Mr. Pesicka serves on the public company board of directors of Fortrea, where he is a member of the Audit Committee and the Management Development & Compensation Committee. - Edward A. Pesicka，他是Owens & Minor， Inc.的总裁兼首席执行官，自2019年3月以来一直担任该职位。此前，Pesicka先生自2016年1月1日起担任医疗保健、生命科学和分销行业的独立顾问和顾问。从2000年1月到2015年4月，他担任Thermo Fisher Scientific Inc.的各种职务，包括首席商务官和高级副总裁（从2014年1月到2015年4月）。在此之前，他从2008年7月到2014年1月担任Thermo Fisher的客户渠道总裁，从2006年11月到2008年7月担任研究市场总裁。在他的职业生涯早期，他在Thermo Fischer Scientific的财务部门担任过各种副总裁级别的职位，担任多个部门的首席财务官。在加入Thermo Fisher Scientific之前，他在TRW， Inc.的财务部门工作了8年，在PricewaterhouseCoopers担任审计员3年。Pesicka先生担任Fortrea的上市公司董事会成员，在那里他是审计委员会和管理发展与薪酬委员会的成员。
- Edward A. Pesicka is the President and Chief Executive Officer of Accendra Health, Inc. a position he has held since March 2019. Previously Mr. Pesicka served as an independent consultant and advisor in the healthcare, life sciences and distribution industries since January 1, 2016. From January 2000 through April 2015, Mr. Pesicka served in various roles of increasing responsibility at Thermo Fisher Scientific Inc., including, Chief Commercial Officer and Senior Vice President from January 2014 to April 2015. Prior to that, he was President, Customer Channels at Thermo Fisher from July 2008 to January 2014 and President, Research Market from November 2006 to July 2008. Earlier in his career, Mr. Pesicka held various Vice President level roles in Thermo Fischer Scientific's finance department, serving as Chief Financial Officer of numerous divisions. Prior to Thermo Fisher Scientific, Mr. Pesicka spent eight years with TRW, Inc. in its finance department and three years with PricewaterhouseCoopers as an auditor. Mr. Pesicka serves on the public company board of directors of Fortrea, where he is a member of the Audit Committee and the Management Development & Compensation Committee.
高管简历
中英对照 | 中文 | 英文- Andrew G. Long
AndrewG.Long，自2019年11月11日加入公司以来，担任Owens&Minor的执行Vice President和首席财务官。在此之前，龙先生于2019年4月至2019年11月8日担任InsysTherapeutics，Inc.的首席执行官。在此之前，龙先生于2017年8月起担任Insys的首席财务官。在加入Insys之前，龙先生于2015年至2017年担任制药公司Patheon的全球财务高级副总裁。在Patheon工作之前，龙先生于2006年至2015年担任Thermo Fisher Scientific多个部门的财务Vice President。龙先生自2019年4月起担任Insys的董事会成员，该公司于2019年6月申请第11章破产保护，直到他于2019年11月8日辞职。
Andrew G. Long,Executive Vice President & Chief Executive Officer of Products & Healthcare Services Segment since October 2022. Previously Mr. Long served as Chief Financial Officer of Owens & Minor since joining the Company in November 2019. Prior to that, Mr. Long served as the Chief Executive Officer and as a board member of Insys Therapeutics, Inc. (Insys), from April 2019 to November 8, 2019. Insys filed for Chapter 11 bankruptcy protection in June 2019. Prior to that, Mr. Long served as the Chief Financial Officer of Insys from August 2017. Prior to joining Insys, Mr. Long served as Senior Vice President of Global Finance at Patheon, a pharmaceutical company, from 2015 to 2017. Prior to working at Patheon, Mr. Long served as Vice President of Finance for multiple divisions at Thermo Fisher Scientific from 2006 until 2015.- AndrewG.Long，自2019年11月11日加入公司以来，担任Owens&Minor的执行Vice President和首席财务官。在此之前，龙先生于2019年4月至2019年11月8日担任InsysTherapeutics，Inc.的首席执行官。在此之前，龙先生于2017年8月起担任Insys的首席财务官。在加入Insys之前，龙先生于2015年至2017年担任制药公司Patheon的全球财务高级副总裁。在Patheon工作之前，龙先生于2006年至2015年担任Thermo Fisher Scientific多个部门的财务Vice President。龙先生自2019年4月起担任Insys的董事会成员，该公司于2019年6月申请第11章破产保护，直到他于2019年11月8日辞职。
- Andrew G. Long,Executive Vice President & Chief Executive Officer of Products & Healthcare Services Segment since October 2022. Previously Mr. Long served as Chief Financial Officer of Owens & Minor since joining the Company in November 2019. Prior to that, Mr. Long served as the Chief Executive Officer and as a board member of Insys Therapeutics, Inc. (Insys), from April 2019 to November 8, 2019. Insys filed for Chapter 11 bankruptcy protection in June 2019. Prior to that, Mr. Long served as the Chief Financial Officer of Insys from August 2017. Prior to joining Insys, Mr. Long served as Senior Vice President of Global Finance at Patheon, a pharmaceutical company, from 2015 to 2017. Prior to working at Patheon, Mr. Long served as Vice President of Finance for multiple divisions at Thermo Fisher Scientific from 2006 until 2015.
- Jonathan A. Leon
JonathanA.Leon，自2018年5月起担任Owens&Minor的高级副总裁，公司财务主管。在此之前，Leon先生于2017年1月加入Owens&Minor后担任Vice President兼财务主管。加入Owens&Minor公司之前，他曾任职The Brinks Company19年，在那里他曾担任财务主管（始于1998年）。
Jonathan A. Leon,Executive Vice President and Chief Financial Officer of Owens & Minor since September 2024 and served as interim Chief Financial Officer since June 2024. Previously Mr. Leon served as Senior Vice President, Corporate Treasurer of the Company since May 2018. Prior to that, Mr. Leon served as Vice President, Treasurer, after joining Owens & Minor in January 2017. Before joining Owens & Minor, Mr. Leon worked for Universal Corporation and The Brinks Company for 18 years where he served as Vice President and Treasurer.- JonathanA.Leon，自2018年5月起担任Owens&Minor的高级副总裁，公司财务主管。在此之前，Leon先生于2017年1月加入Owens&Minor后担任Vice President兼财务主管。加入Owens&Minor公司之前，他曾任职The Brinks Company19年，在那里他曾担任财务主管（始于1998年）。
- Jonathan A. Leon,Executive Vice President and Chief Financial Officer of Owens & Minor since September 2024 and served as interim Chief Financial Officer since June 2024. Previously Mr. Leon served as Senior Vice President, Corporate Treasurer of the Company since May 2018. Prior to that, Mr. Leon served as Vice President, Treasurer, after joining Owens & Minor in January 2017. Before joining Owens & Minor, Mr. Leon worked for Universal Corporation and The Brinks Company for 18 years where he served as Vice President and Treasurer.
- Perry A. Bernocchi
自2023年3月起担任Patient Direct Segment执行副总裁兼首席执行官的佩里·贝诺基（Perry Bernocchi）。在此之前，Bernocchi先生曾担任公司Byram Healthcare部门的总裁兼首席执行官，自2009年起担任该职位。Bernocchi先生于2006年加入Byram Healthcare，担任首席运营官。在此之前，Bernocchi先生曾于2000年至2005年担任美国血友病资源公司的首席运营官，之后该公司被出售给Accredo Health。在此之前，Bernocchi先生曾于1982年至2000年在Caremark/Coram工作，在Coram资源网络内担任越来越多的运营和一般管理职责，并担任运营高级副总裁。
Perry A. Bernocchi,Executive Vice President & Chief Executive Officer of Patient Direct Segment since March 2023. Prior to that, Mr. Bernocchi served as President & Chief Executive Officer of the Company's Byram Healthcare division, a position he held since 2009. Mr. Bernocchi joined Byram Healthcare in 2006 as its Chief Operating Officer. Prior to that, Mr. Bernocchi served as Chief Operating Officer of Hemophilia Resources of America from 2000 to 2005 prior to its sale to Accredo Health. Prior to that, Mr. Bernocchi worked for Caremark/Coram from 1982 to 2000 in various roles of increasing responsibility in operations and general management within Coram Resource Network and as Senior Vice President of Operations.- 自2023年3月起担任Patient Direct Segment执行副总裁兼首席执行官的佩里·贝诺基（Perry Bernocchi）。在此之前，Bernocchi先生曾担任公司Byram Healthcare部门的总裁兼首席执行官，自2009年起担任该职位。Bernocchi先生于2006年加入Byram Healthcare，担任首席运营官。在此之前，Bernocchi先生曾于2000年至2005年担任美国血友病资源公司的首席运营官，之后该公司被出售给Accredo Health。在此之前，Bernocchi先生曾于1982年至2000年在Caremark/Coram工作，在Coram资源网络内担任越来越多的运营和一般管理职责，并担任运营高级副总裁。
- Perry A. Bernocchi,Executive Vice President & Chief Executive Officer of Patient Direct Segment since March 2023. Prior to that, Mr. Bernocchi served as President & Chief Executive Officer of the Company's Byram Healthcare division, a position he held since 2009. Mr. Bernocchi joined Byram Healthcare in 2006 as its Chief Operating Officer. Prior to that, Mr. Bernocchi served as Chief Operating Officer of Hemophilia Resources of America from 2000 to 2005 prior to its sale to Accredo Health. Prior to that, Mr. Bernocchi worked for Caremark/Coram from 1982 to 2000 in various roles of increasing responsibility in operations and general management within Coram Resource Network and as Senior Vice President of Operations.
- Heath H. Galloway
Heath Galloway，自2023年5月起担任执行副总裁、总法律顾问兼公司秘书。在此之前，2016年4月至2023年5月，加洛韦先生担任协理总法律顾问。在此之前，Galloway先生于2013年2月加入欧麦斯-麦能医疗后担任助理总法律顾问。在加入欧麦斯-麦能医疗之前，Galloway先生在威廉姆斯 Mullen工作了九年。
Heath H. Galloway,Executive Vice President, General Counsel & Corporate Secretary since May 2023. Prior to that, from April 2016 to May 2023, Mr. Galloway served as Associate General Counsel. Prior to that, Mr. Galloway served as Assistant General Counsel after joining Owens & Minor in February 2013. Prior to joining Owens & Minor, Mr. Galloway worked at Williams Mullen for nine years.- Heath Galloway，自2023年5月起担任执行副总裁、总法律顾问兼公司秘书。在此之前，2016年4月至2023年5月，加洛韦先生担任协理总法律顾问。在此之前，Galloway先生于2013年2月加入欧麦斯-麦能医疗后担任助理总法律顾问。在加入欧麦斯-麦能医疗之前，Galloway先生在威廉姆斯 Mullen工作了九年。
- Heath H. Galloway,Executive Vice President, General Counsel & Corporate Secretary since May 2023. Prior to that, from April 2016 to May 2023, Mr. Galloway served as Associate General Counsel. Prior to that, Mr. Galloway served as Assistant General Counsel after joining Owens & Minor in February 2013. Prior to joining Owens & Minor, Mr. Galloway worked at Williams Mullen for nine years.
- Edward A. Pesicka
Edward A. Pesicka，他是Owens & Minor， Inc.的总裁兼首席执行官，自2019年3月以来一直担任该职位。此前，Pesicka先生自2016年1月1日起担任医疗保健、生命科学和分销行业的独立顾问和顾问。从2000年1月到2015年4月，他担任Thermo Fisher Scientific Inc.的各种职务，包括首席商务官和高级副总裁（从2014年1月到2015年4月）。在此之前，他从2008年7月到2014年1月担任Thermo Fisher的客户渠道总裁，从2006年11月到2008年7月担任研究市场总裁。在他的职业生涯早期，他在Thermo Fischer Scientific的财务部门担任过各种副总裁级别的职位，担任多个部门的首席财务官。在加入Thermo Fisher Scientific之前，他在TRW， Inc.的财务部门工作了8年，在PricewaterhouseCoopers担任审计员3年。Pesicka先生担任Fortrea的上市公司董事会成员，在那里他是审计委员会和管理发展与薪酬委员会的成员。
Edward A. Pesicka is the President and Chief Executive Officer of Accendra Health, Inc. a position he has held since March 2019. Previously Mr. Pesicka served as an independent consultant and advisor in the healthcare, life sciences and distribution industries since January 1, 2016. From January 2000 through April 2015, Mr. Pesicka served in various roles of increasing responsibility at Thermo Fisher Scientific Inc., including, Chief Commercial Officer and Senior Vice President from January 2014 to April 2015. Prior to that, he was President, Customer Channels at Thermo Fisher from July 2008 to January 2014 and President, Research Market from November 2006 to July 2008. Earlier in his career, Mr. Pesicka held various Vice President level roles in Thermo Fischer Scientific's finance department, serving as Chief Financial Officer of numerous divisions. Prior to Thermo Fisher Scientific, Mr. Pesicka spent eight years with TRW, Inc. in its finance department and three years with PricewaterhouseCoopers as an auditor. Mr. Pesicka serves on the public company board of directors of Fortrea, where he is a member of the Audit Committee and the Management Development & Compensation Committee.- Edward A. Pesicka，他是Owens & Minor， Inc.的总裁兼首席执行官，自2019年3月以来一直担任该职位。此前，Pesicka先生自2016年1月1日起担任医疗保健、生命科学和分销行业的独立顾问和顾问。从2000年1月到2015年4月，他担任Thermo Fisher Scientific Inc.的各种职务，包括首席商务官和高级副总裁（从2014年1月到2015年4月）。在此之前，他从2008年7月到2014年1月担任Thermo Fisher的客户渠道总裁，从2006年11月到2008年7月担任研究市场总裁。在他的职业生涯早期，他在Thermo Fischer Scientific的财务部门担任过各种副总裁级别的职位，担任多个部门的首席财务官。在加入Thermo Fisher Scientific之前，他在TRW， Inc.的财务部门工作了8年，在PricewaterhouseCoopers担任审计员3年。Pesicka先生担任Fortrea的上市公司董事会成员，在那里他是审计委员会和管理发展与薪酬委员会的成员。
- Edward A. Pesicka is the President and Chief Executive Officer of Accendra Health, Inc. a position he has held since March 2019. Previously Mr. Pesicka served as an independent consultant and advisor in the healthcare, life sciences and distribution industries since January 1, 2016. From January 2000 through April 2015, Mr. Pesicka served in various roles of increasing responsibility at Thermo Fisher Scientific Inc., including, Chief Commercial Officer and Senior Vice President from January 2014 to April 2015. Prior to that, he was President, Customer Channels at Thermo Fisher from July 2008 to January 2014 and President, Research Market from November 2006 to July 2008. Earlier in his career, Mr. Pesicka held various Vice President level roles in Thermo Fischer Scientific's finance department, serving as Chief Financial Officer of numerous divisions. Prior to Thermo Fisher Scientific, Mr. Pesicka spent eight years with TRW, Inc. in its finance department and three years with PricewaterhouseCoopers as an auditor. Mr. Pesicka serves on the public company board of directors of Fortrea, where he is a member of the Audit Committee and the Management Development & Compensation Committee.